Pharmaceutical company Breckenridge Pharmaceutical Inc reported on Tuesday the receipt of US Food and Drug Administration final approval for an Abbreviated New Drug Application for Erlotinib Hydrochloride Tablets (generic Tarceva) in EQ 25mg base, EQ 100mg base and EQ 150mg base strengths for the treatment of non-small cell lung cancer and pancreatic cancer.
The Abbreviated New Drug Application of Erlotinib Hydrochloride Tablets is reportedly held by Natco Pharma Limited and developed in collaboration with MEDIK Ltd.
Under Breckenridge's marketing, sale and distribution agreement, the Erlotinib Hydrochloride Tablets will be manufactured and supplied by Natco and Breckenridge plans to launch the product immediately.
According to industry sales data, Tarceva and its therapeutic equivalents generated annual sales of approximately USD145m in the year ended 30 September 2019.
Viatris names new chief legal officer
Alvotech signs biosimilar supply and commercialisation deals with Sandoz
InSysBio agrees new collaborative project with BeOne Medicines
MS Pharma enters strategic partnership with Hetero Group
Apiject to open new generic injectable drug manufacturing facility in Apex, NC
Bionpharma and STEERLife's Etravirine tablets approved by US FDA
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
Accord Healthcare launches Clomiphene tablets in US market
Zentiva receives ESG Transparency Award 2025
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz